For patients with multiple myeloma, autologous stem-cell transplantation (SCT) has been a standard treatment; however, up to 50% of patients do not achieve a response following transplantation. Nonetheless, a lack of a response to induction therapy does not impact progression-free survival or overall survival outcomes, although this finding has only been assessed in patients treated with conventional therapies. A retrospective study by Gertz et al. showed that patients who do not achieve partial remission have a significantly shorter overall survival post-transplantation.
The study assessed 286 patients who had at least a partial response to thalidomide-based or lenalidomide-based therapy. The complete response and very good partial response (VGPR) rates were significantly higher for patients in the plateau (responding) group before transplantation compared with those in the relapsed-refractory group. Moreover, progression occurred in 83% who were refractory to treatment compared with 56% who showed a response. The overall survival was 75% in patients with a VGPR, and 54% in those without such a response.
Interesting, in those with a VGPR after transplantation, no survival advantage was conveyed for those achieving a pretransplantation response to novel agents, although the study was limited by a small sample size and short follow-up. “Absence of a response to induction therapy with thalidomide or lenalidomide predicts a poorer outcome after high-dose therapy”, concludes Gertz “More effective induction schemes are needed to ensure response [is] achieved prior to SCT”.
ORIGINAL RESEARCH PAPER
Gertz, M. A. et al. Stem cell transplantation in multiple myeloma: impact of response failure with thalidomide or lenalidomide induction. Blood 115, 2348–2353 (2010)
Rights and permissions
About this article
Cite this article
Hutchinson, L. Poor outcome to induction therapy for nonresponders. Nat Rev Clin Oncol 7, 299 (2010). https://doi.org/10.1038/nrclinonc.2010.78
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2010.78